A substantial advancement in diabetes treatment is emerging with the release of tirzepatide at a dosage of 45mg. This updated formulation builds upon the existing success of tirzepatide, a dual GIP and GLP-1 agonist, https://zaynjkfh617156.techionblog.com/40992717/significant-approach-tirzepatide-45mg-for-diabetes-management